A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in Participants Aged 18 Years and Over in China
Latest Information Update: 10 Jul 2023
At a glance
- Drugs LVRNA 021 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors AIM Vaccine
- 12 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 03 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Feb 2023.
- 16 Dec 2022 Status changed from active, no longer recruiting to recruiting.